Cannabis Science Enthused With CNN Monitoring The Outcome Of The National State By State Voting To Legalize Medical Cannabis
Cannabis Science Expresses Optimism as Voters Take The Polls Across the Nation
COLORADO SPRINGS, Colo., Nov. 5, 2014 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is closely monitoring the CNN reporting of the outcome of the State by State voting to legalize medical cannabis. Target States in this voting session are Washington DC, Florida, Oregon, and Alaska.
Please visit: https://www.cnn.com/2014/11/04/politics/marijuana-2014
The Company believes the Washington DC, approval is the most significant. Being the center of our federal political influential movements, it plays a key role influencing medical cannabis state-by-state initiatives as well as Federal laws governing the medical research on this plant.
Currently, 23 states and the District of Columbia have passed laws allowing some degree of medical use of cannabis. With this as the backdrop, the Company believes this could lead to further acceptance and improvement of regulatory environment around medical cannabis in the United States and around the World, continuing with the domino effect that will benefit patients who have to rely on medical marihuana and deserve to receive quality assured medication in the context of the general healthcare.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Robert Kane, CFO & Director
Cannabis Science, Inc.
Raymond C. Dabney, Management Consultant, Co-Founder
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | firstname.lastname@example.org